Business Wire

SEOUL-VIOSYS/TYPHON

27.6.2022 10:47:08 CEST | Business Wire | Press release

Share
Seoul Viosys 'Violeds' UV-C Technology Applied to 30,000 Cubic Meters Per Day for Municipal Water Purification System from Typhon Treatment Systems

Seoul Viosys (KOSDAQ: 092190), a company specializing in optical semiconductors, announced that the ‘Violeds’ technology was supplied to Typhon Treatment Systems Ltd. , a British water treatment company, and applied to the UK's Cumbria water purification plant with a daily water purification capacity of 30,000 cubic meters.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005267/en/

UV lamp sterilization using mercury has been used in water purification facilities for the past several decades, and despite the restrictions on mercury products by the Minamata Convention, it was difficult to replace the sterilization performance, so it was subject to special permission. However, Violeds uses LEDs as a UV source, so it does not use mercury and reduces the amount of chemicals used for sterilization, thereby reducing the occurrence of environmental problems. In addition, an energy-efficient operation is possible through easy automatic control according to water usage thereby reducing operating costs compared to facilities using existing UV lamps. In particular, the expected effect is large in facilities such as water purification plants that need to be operated for a long time.

Typhon's BIO-310 UV LED Reactor, installed in the Cumbria water purification plant in the UK with Violeds applied, has an optimal design for the arrangement and operation of UV LEDs, and can process 30,000 cubic meters of water per day. BIO-310 was selected as a winner in the water supply field at Aquatech Amsterdam 2021, the largest water treatment exhibition in Europe and the most influential one in the world.

According to a Typhon official, the UV application market is around USD 950 million out of the USD 400 billion water treatment market per year. UV technology can protect water from Cryptosporidium, which is difficult to sterilize with chlorine, so it is expected to be expanded to water purification plants around the world in the coming few years when the improvements in efficiency of the UV LEDs and cost decrease will make even more attractive the return on investment. Within the next 2 years, we see the tipping point where LED power/efficiency development changes the scenario from ‘Why use LED’ to ‘Why not use LED’.

Oliver Schafer, EVP Seoul Viosys & Seoul Semiconductor Sales Division, underlines: “In order to prevent water quality accidents due to occurrence of algae and larvae in tap water every year, our proprietary Violeds technology provides fundamental advantages compared to legacy mercury lamp usage and the resulting environmental damage effects. Our research team is spurring R&D of Violeds technology so that you can trust and drink it in an environmentally friendly way.”

About Typhon Treatment Systems Ltd.

In 2013, Typhon’s founders, Dr. Matthew Simpson and Peter McNulty were working together on an off-grid municipal scale water project in Nigeria. The need for a sustainable and simplistic solution inspired them to investigate the possibility of using Mercury Free high flow LED ultraviolet (UV) water treatment equipment. None existed, and no existing UV water treatment equipment supplier would build one for them. In 2014, Typhon Treatment Systems was formed to create it. We now deliver a UV LED solution that is 100% mercury-free, reduces maintenance, and dramatically reduces ancillary infrastructure (Glass/Mercury traps).

At this time we focus on two main applications leveraging UVC LEDs:

  • Biological disinfection for inactivation of pathogens
  • Photochemical oxidation processes for removal of chemical water contaminants

Typhon’s USEPA UVDGM validated BIO-310 reactor is the only Municipal scale UV LED system available today. Typhon has collaborated with United Utilities to deliver the world’s largest UV LED for drinking water disinfection installation, with the capacity to treat nearly 30,000m3 /day.

https://www.typhontreatment.com/

Media contact:
Mike Hemingway
mhemingway@typhontreatment.com

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 6,800 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .

Link:

ClickThru

Social Media:

https://www.facebook.com/violedsTechnologykorea/?brand_redir=1698430287094913

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an

Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release

Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye